2025 Global Antiviral Drugs Market Revenue Opportunities Report
Description
The 2025 Global Antiviral Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antiviral Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global antiviral drugs market are Gilead Sciences, Merck & Co., GlaxoSmithKline (GSK), and Pfizer. Gilead Sciences leads this market with major antiviral drugs like Biktarvy and Genvoya, which are pivotal in HIV treatment, driving significant revenue and innovation efforts. Merck & Co. remains a dominant pharma player, with robust revenue driven by key products and ongoing expansion in antiviral pipelines, despite challenges such as patent expirations and market fluctuations. GSK contributes strongly with blockbuster antiretroviral therapies like Triumeq, enhancing its market position through continuous R&D and strategic global distribution. Pfizer, consistently ranking high in pharmaceutical sales, has expanded its antiviral portfolio through acquisitions such as ReViral, focusing on respiratory syncytial virus and other infectious diseases.
These companies benefit from extensive research investments, global distribution networks, and strategic partnerships to innovate and broaden antiviral treatment options addressing diseases like HIV, influenza, hepatitis, and emerging viral threats. The antiviral drug market is expected to grow steadily, driven by these leaders' development of new combination therapies, novel drug delivery systems, and targeted antiviral agents supported by strong clinical pipelines and government funding. Their global presence and active participation in antiviral R&D solidify their positions as key drivers in managing viral infections worldwide.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antiviral Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global antiviral drugs market are Gilead Sciences, Merck & Co., GlaxoSmithKline (GSK), and Pfizer. Gilead Sciences leads this market with major antiviral drugs like Biktarvy and Genvoya, which are pivotal in HIV treatment, driving significant revenue and innovation efforts. Merck & Co. remains a dominant pharma player, with robust revenue driven by key products and ongoing expansion in antiviral pipelines, despite challenges such as patent expirations and market fluctuations. GSK contributes strongly with blockbuster antiretroviral therapies like Triumeq, enhancing its market position through continuous R&D and strategic global distribution. Pfizer, consistently ranking high in pharmaceutical sales, has expanded its antiviral portfolio through acquisitions such as ReViral, focusing on respiratory syncytial virus and other infectious diseases.
These companies benefit from extensive research investments, global distribution networks, and strategic partnerships to innovate and broaden antiviral treatment options addressing diseases like HIV, influenza, hepatitis, and emerging viral threats. The antiviral drug market is expected to grow steadily, driven by these leaders' development of new combination therapies, novel drug delivery systems, and targeted antiviral agents supported by strong clinical pipelines and government funding. Their global presence and active participation in antiviral R&D solidify their positions as key drivers in managing viral infections worldwide.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
